Exact Sciences: Q3 Sell-Off May Be Unjustified, But Long-Term Outlook A Concern
Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...
Business Wire15d
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement
“Exact Sciences is pleased to share new modeling data which demonstrates the Cologuard Plus test as an ... with an average of 25.5 days to return the kit; This supports mt-sDNA as an effective ...
Joplin Globe15d
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement ...
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.
Yahoo Finance5d
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...